Moderna (NASDAQ:MRNA) Downgraded by Jefferies Financial Group to “Hold”

Jefferies Financial Group lowered shares of Moderna (NASDAQ:MRNA) from a buy rating to a hold rating in a report issued on Friday morning, Marketbeat reports. They currently have $65.00 price objective on the stock, down from their prior price objective of $120.00.

MRNA has been the subject of a number of other research reports. JPMorgan Chase & Co. lowered Moderna from a neutral rating to an underweight rating and reduced their target price for the stock from $88.00 to $70.00 in a research note on Friday. Evercore ISI reaffirmed an in-line rating and set a $120.00 target price on shares of Moderna in a report on Thursday, June 27th. The Goldman Sachs Group dropped their target price on Moderna from $204.00 to $178.00 and set a buy rating on the stock in a research report on Friday, August 2nd. HSBC raised shares of Moderna from a reduce rating to a hold rating and set a $82.00 price target for the company in a research report on Wednesday, August 28th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a sell rating to a hold rating and cut their price objective for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Moderna currently has a consensus rating of Hold and a consensus price target of $108.53.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $68.28 on Friday. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The company has a market cap of $26.17 billion, a PE ratio of -4.36 and a beta of 1.67. The business has a 50-day simple moving average of $95.06 and a two-hundred day simple moving average of $111.89.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same period last year, the business earned ($3.62) EPS. Moderna’s revenue for the quarter was down 29.9% on a year-over-year basis. As a group, equities analysts expect that Moderna will post -9.52 EPS for the current fiscal year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The disclosure for this sale can be found here. Insiders sold a total of 93,158 shares of company stock valued at $11,167,312 in the last three months. 15.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Moderna

Large investors have recently modified their holdings of the business. Cedar Wealth Management LLC grew its stake in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Commerzbank Aktiengesellschaft FI lifted its position in Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after buying an additional 93 shares in the last quarter. CVA Family Office LLC boosted its stake in Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after buying an additional 96 shares during the last quarter. Claro Advisors LLC increased its stake in shares of Moderna by 2.0% in the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after acquiring an additional 108 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Moderna by 32.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after acquiring an additional 116 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.